Protein S100 Beta as a Predictor of Resuscitation Outcome
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Management of cardiac arrest is complicated by the lack of a readily available tool identifying individuals who are likely to be successfully resuscitated. S100 beta is a protein that originates in the astroglial cells of the brain, and NSE (Neuron Specific Enolase) is another protein that originates in the neurons themselves. In the laboratory, the concentration of these proteins correlate with evidence of brain damage after head trauma, stroke and exposure to low levels of oxygen. The concentration of these proteins in the blood of human survivors of cardiopulmonary resuscitation in humans is much higher than in patients who were resuscitated but did not survive. However, it is still unclear whether survivors from cardiopulmonary resuscitation have higher levels of these proteins in their blood if they survive with neurological injury secondary to the arrest and resuscitation.
Hypothesis: In humans, the blood concentrations of protein S100 beta and NSE during and after resuscitation can predict who will die despite cardiopulmonary resuscitation and who will survive with neurological injury secondary to the arrest and resuscitation.
| Condition |
|---|
|
Cardiopulmonary Arrest Outcome |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort |
| Official Title: | Protein S100 Beta as a Predictor of the Outcome of Cardiopulmonary Resuscitation |
Blood
| Estimated Enrollment: | 600 |
| Study Start Date: | August 2008 |
| Estimated Study Completion Date: | January 2012 |
| Groups/Cohorts |
|---|
| Cardiopulmonary arrest |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
All victims of non-traumatic out-of hospital cardiopulmonary arrest (defined as the absence of either spontaneous respiration or palpable pulse or both) within the Jerusalem district.
Inclusion Criteria:
- All victims of non-traumatic out-of hospital cardiopulmonary arrest (defined as the absence of either spontaneous respiration or palpable pulse or both) within the Jerusalem district.
Exclusion Criteria:
- Patients with do-not-resuscitate orders or an advance directive to that effect.
- Patients with intracranial hemorrhage
Contacts and Locations| Contact: Sharon Einav, MD | 972-508-685480 | einav_s@szmc.org.il |
| Israel | |
| Shaare Zedek Medical Center | Recruiting |
| Jerusalem, Israel, 91031 | |
| Contact: Sharon Einav, MD 972-508-685480 einav_s@szmc.org.il | |
| Contact: Nechama M Kaufman, MN 972-508-685324 nechamak@szmc.org.il | |
| Hadassah Medical Center | Recruiting |
| Jerusalem, Israel, 91120 | |
| Contact: Jeremy D Kark, MD, PhD 972-2-6777113 jeremy1@vms.huji.ac.il | |
| Principal Investigator: | Sharon Einav, MD | Shaare Zedek Medical Center |
More Information
No publications provided by Shaare Zedek Medical Center
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Sharon Einav, MD. Director of Surgical ICU, Shaare Zedek Medical Center |
| ClinicalTrials.gov Identifier: | NCT00814814 History of Changes |
| Other Study ID Numbers: | 14-01-05 A and B (correction) |
| Study First Received: | December 24, 2008 |
| Last Updated: | May 23, 2011 |
| Health Authority: | Israel: Ministry of Health |
Additional relevant MeSH terms:
|
Heart Arrest Heart Diseases Cardiovascular Diseases Protein S |
Anticoagulants Hematologic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 21, 2013